VRCA
Verrica Pharmaceuticals Inc (VRCA)
Healthcare • NASDAQ • $3.47-3.48%
- Symbol
- VRCA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.47
- Daily Change
- -3.48%
- Market Cap
- $61.76M
- Trailing P/E
- N/A
- Forward P/E
- -2.43
- 52W High
- $9.82
- 52W Low
- $3.28
- Analyst Target
- $13.83
- Dividend Yield
- 0.00%
- Beta
- 1.61
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization o…
Company websiteResearch VRCA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.